HIF1A and pancreatic ductal adenocarcinoma: Zhao et al. found that the HIF-1α inhibitor, PX-478 enhanced the anti-tumor effect of gemcitabine, a first-line chemotherapeutic drug for advanced pancreatic cancer, in pancreatic ductal adenocarcinoma [43].